Stanford School

Eight Sleep Appoints Dr. Andrew Huberman, Dr. Matthew Walker, and Dr. Peter Attia to Its Scientific Advisory Board

Retrieved on: 
Giovedì, Maggio 30, 2024
Research, Technology, Neurology, Health Technology, Software, Hardware, Health, Consumer Electronics, Science, Artificial Intelligence, Sleep, Intelligence, Machine learning, Exercise, Eight Sleep, University, Light, Stanford School, Mental health, Database, Fitness, Snoring, Longevity, Growth, REM, Why We Sleep, Brain, Artificial intelligence, Psychology, Pod, Entrepreneurship, Pharmaceutical industry

Eight Sleep , the world’s first sleep fitness company, announces the additions of Dr. Andrew Huberman, Dr. Matthew Walker, and Dr. Peter Attia to its Scientific Advisory Board .

Key Points: 
  • Eight Sleep , the world’s first sleep fitness company, announces the additions of Dr. Andrew Huberman, Dr. Matthew Walker, and Dr. Peter Attia to its Scientific Advisory Board .
  • With a foundation built on over 500 million hours of sleep data, Eight Sleep boasts one of the largest sleep datasets in the world today.
  • "At Eight Sleep, we’ve transformed how people sleep and ultimately perform, and we’re just getting started.
  • For more information on Eight Sleep’s Scientific Advisory Board and its revolutionary sleep solutions, visit eightsleep.com .

Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia

Retrieved on: 
Lunedì, Maggio 6, 2024
Boehringer Ingelheim, Safety, Risk, Tissue, Diabetic retinopathy, Abstract, Research, Ingelheim am Rhein, Stanford School, Light, Principal, Master of Science, Paratriathlon, Geographic atrophy, Pediatrics, DMI, Quality of life, ARVO, DR, Medical device

Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic macular ischemia (DMI).

Key Points: 
  • Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic macular ischemia (DMI).
  • The current standard of care for advanced DR includes intravitreal anti-VEGF treatment or invasive laser treatment.
  • “Retinal non-perfusion is a key driver of vision loss in people living with diabetic retinopathy.
  • However, until the HORNBILL study, retinal non-perfusion has not been explored as a potential treatment target.”
    “Vision loss associated with retinal conditions such as diabetic retinopathy and DMI has a devastating impact on quality of life.

5 Ways Heart Health Care Can Improve

Retrieved on: 
Lunedì, Aprile 29, 2024
The Harris Poll, Education, Brain, Public, Cancer, Food, Disorder, FAHA, Stroke, Pneumonia, Housing, Prevalence, CVD, Risk, Health, Infection, Heart, Radiology, Death, Research, Artificial intelligence, Life, Stanford School, Disease, Moyamoya disease, Physician, Cardiovascular disease, Diphtheria, Roflumilast, Tuberculosis, Overalls, American Heart Association, Heart failure, Pharmaceutical industry

"Finding that most people do not know the significant impact of heart disease is discouraging and even a bit frightening."

Key Points: 
  • "Finding that most people do not know the significant impact of heart disease is discouraging and even a bit frightening."
  • Non-traditional approaches to health care are needed to address the social and structural determinants of health by moving evidence-based approaches rapidly into communities to address food insecurity, transportation problems, education, housing, access to care, chronic psychosocial stress and other social needs.
  • The interconnectedness of organ systems, mechanisms of disease and stages of life are critical to understanding the role cardiovascular health plays in overall health.
  • As we apply these same clinical and epidemiological methods to the someday hopeful eradication of heart disease and stroke, the American Heart Association is making great progress.

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology

Retrieved on: 
Lunedì, Aprile 29, 2024
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Oncology, Health Technology, Other Science, Research, Genetics, Science, Stanford University, Hospital, Nobel Prize, RNA, GlycoRNA, Cell, Boston, Humanities, Stanford School, Renegade, Patient, Assistant, Therapy

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem.

Key Points: 
  • ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem.
  • GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade.
  • “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade.
  • Glycobiology-based RNA medicines represent a new frontier, and it is rewarding to see the possibilities of ReNAgade developing these for clinical use.”

Stanford Medicine Children's Health Welcomes New Chief of the Division of Abdominal Transplantation

Retrieved on: 
Mercoledì, Aprile 24, 2024
Stanford University, University, Patient, Kidney, Transplant, Columbia University, Doctor of Philosophy, Research, UC, Stanford School, Liver, PALO, University of California, Berkeley, Molecular biology, Algorithm, Division, Growth, Dentistry

PALO ALTO, Calif., April 24, 2024 /PRNewswire/ -- Marc Melcher, MD , has been appointed the new Chief of the Division of Abdominal Transplantation at Stanford Medicine .

Key Points: 
  • PALO ALTO, Calif., April 24, 2024 /PRNewswire/ -- Marc Melcher, MD , has been appointed the new Chief of the Division of Abdominal Transplantation at Stanford Medicine .
  • In his new role, he oversees all aspects of abdominal transplant programs, including liver, kidney, and small bowel transplantation at Stanford Medicine Children's Health.
  • Dr. Melcher follows Carlos O. Esquivel, MD , who has been Division Chief since 1998.
  • In addition, Dr. Melcher is a professor of surgery at the Stanford School of Medicine and the current Abdominal Transplant Fellowship Director.

NeuroVigil, World’s Most Valuable Neurotech, Launches iBrain™ in US

Retrieved on: 
Venerdì, Aprile 5, 2024
Head, Roche, MIT Technology Review, IP, FCCP, Clinic, Seed, Consciousness, Partnership, Novartis, SAN, DNA, Aneurysm, Critical care, Stanford School, Cedars-Sinai Medical Center, Lawyer, Harvard Medical School, DSS, University, MD, Hospital, FDA, Apnea, Brain, ALS, MIT, Neocortex, Biomarker, Bird, Doctor of Philosophy, Human, Brain tumor, BCIS, Silicon, Patent, VCS, Division

The investigators will initially not be allowed to modify anyone’s therapy based on iBrain data.

Key Points: 
  • The investigators will initially not be allowed to modify anyone’s therapy based on iBrain data.
  • A joint abstract by Dr. Low and Dr. Hawking featuring Dr. Hawking’s brain patterns analyzed by NeuroVigil’s technology was released as early as 2012.
  • The technology was also successfully demonstrated on ALS sufferer Augie Nieto in 2013 who spelled “COMMUNICATE” with his mind.
  • In the past two years, NeuroVigil has recruited talent from Amgen, Roche, Novartis and MIT in preparation for the launch.

CORRECTION -- NeuroVigil, World’s Most Valuable Neurotech Company, Launches in US

Retrieved on: 
Venerdì, Aprile 5, 2024
Head, Roche, MIT Technology Review, IP, FCCP, Clinic, Seed, Consciousness, Partnership, Novartis, SAN, DNA, Aneurysm, Critical care, Stanford School, Cedars-Sinai Medical Center, Lawyer, Harvard Medical School, DSS, University, MD, Hospital, FDA, Apnea, Brain, ALS, MIT, Neocortex, Biomarker, Bird, Doctor of Philosophy, Human, Brain tumor, BCIS, Patent, VCS, Division

“Who needs implants when you have the real deal?” said Dr. Philip Low, PhD, NeuroVigil’s Chairman, Chief Executive and Technology Officer, Founder and Supermajority Owner.

Key Points: 
  • “Who needs implants when you have the real deal?” said Dr. Philip Low, PhD, NeuroVigil’s Chairman, Chief Executive and Technology Officer, Founder and Supermajority Owner.
  • The investigators will initially not be allowed to modify anyone’s therapy based on iBrain data.
  • The technology was also successfully demonstrated on ALS sufferer Augie Nieto in 2013 who spelled “COMMUNICATE” with his mind.
  • In the past two years, NeuroVigil has recruited talent from Amgen, Roche, Novartis and MIT in preparation for the launch.

NeuroVigil, World’s Most Valuable Neurotech Company, Launches in US

Retrieved on: 
Venerdì, Aprile 5, 2024
Head, Roche, MIT Technology Review, IP, FCCP, Clinic, Seed, Consciousness, Partnership, Novartis, SAN, DNA, Aneurysm, Critical care, Stanford School, Cedars-Sinai Medical Center, Lawyer, Harvard Medical School, DSS, University, MD, Hospital, FDA, Apnea, Brain, ALS, MIT, Neocortex, Biomarker, Bird, Doctor of Philosophy, Human, Brain tumor, BCIS, Silicon, Patent, VCS, Division

The investigators will initially not be allowed to modify anyone’s therapy based on iBrain data.

Key Points: 
  • The investigators will initially not be allowed to modify anyone’s therapy based on iBrain data.
  • A joint abstract by Dr. Low and Dr. Hawking featuring Dr. Hawking’s brain patterns analyzed by NeuroVigil’s technology was released as early as 2012.
  • The technology was also successfully demonstrated on ALS sufferer Augie Nieto in 2013 who spelled “COMMUNICATE” with his mind.
  • In the past two years, NeuroVigil has recruited talent from Amgen, Roche, Novartis and MIT in preparation for the launch.

The Joint Commission Establishes President's Fellowship for Healthcare Quality and Safety

Retrieved on: 
Giovedì, Marzo 14, 2024
Joint, Neuroscience, Learning, Joint Commission, National Quality Forum, Patient, Education, Research, University, Doctor of Philosophy, Howard University Hospital, Stanford School, Stanford University, Health, NQF

OAKBROOK TERRACE, Illinois, March 14, 2024 (GLOBE NEWSWIRE) -- The Joint Commission has established The President’s Fellowship for Healthcare Quality and Safety, a prestigious program for a highly qualified healthcare professional to collaborate with The Joint Commission to advance healthcare outcomes globally.

Key Points: 
  • OAKBROOK TERRACE, Illinois, March 14, 2024 (GLOBE NEWSWIRE) -- The Joint Commission has established The President’s Fellowship for Healthcare Quality and Safety, a prestigious program for a highly qualified healthcare professional to collaborate with The Joint Commission to advance healthcare outcomes globally.
  • The new fellowship, which reports directly to Joint Commission enterprise President and Chief Executive Officer Jonathan B. Perlin, MD, PhD, aligns an accomplished fellow’s specific background and achievements with key Joint Commission initiatives while supporting the Fellow’s career development as an influential leader in quality and safety.
  • “Establishing The President’s Fellowship for Healthcare Quality and Safety is an exciting way to introduce fresh perspectives to The Joint Commission’s efforts to support healthcare organizations’ delivery of safe, high-quality, equitable and compassionate care,” says Dr. Perlin.
  • Applications from mid-career healthcare professionals for The Joint Commission’s 2025 President’s Fellowship for Healthcare Quality and Safety (which spans the calendar year) are currently being accepted.

Tiny and Dr. Andrew Huberman Announce U.S. Debut of Their Majority Owned Canadian Yerba Mate Beverage – Mateina

Retrieved on: 
Giovedì, Gennaio 25, 2024
Software, Finance, Professional Services, Technology, Food, Beverage, Electronic Commerce, Retail, Business, LP, Partnership, Neuroscience, Yerba mate, Coffee, Stanford School, Tea, Whole Foods Market

Tiny (“Tiny” or the “Company”) (TSXV: TINY) a Canadian holding company and Dr. Andrew Huberman announce that their majority owned Canadian Yerba Mate Beverage – Mateina –is now available in the United States via drinkMateina.com .

Key Points: 
  • Tiny (“Tiny” or the “Company”) (TSXV: TINY) a Canadian holding company and Dr. Andrew Huberman announce that their majority owned Canadian Yerba Mate Beverage – Mateina –is now available in the United States via drinkMateina.com .
  • Tiny’s interest in Mateina is held through its private partnership, Tiny Fund I, LP.
  • "Yerba mate has been my preferred source of caffeine for more than three decades," said Dr. Huberman.
  • We're confident that Mateína will make a significant impact in the U.S. health beverage market, bolstered by Dr. Huberman's expertise and the scientific merits of yerba mate."